Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Rolling Out Another Assay
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Cepheid (NASDAQ: CPHD) price target of $50.00.
Analyst, Jeffrey Frelick, said, "We are reiterating our rating on CPHD following CE-mark for its Xpert Chlamydia/gonorrhea (CT/NG) tests. We view commercialization of key tests as important pieces to the mosaic, as CPHD leverages its large installed base across a broad and expanding test menu that drives the important metric, “clinical reagent sales growth.”"
"CT/NG set to kick off in Europe. As expected, CPHD announced CE-mark for CT/NG, bringing its ex-US menu to 13 tests. We expect U.S. approval by yearend."
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $37.68 yesterday.
Analyst, Jeffrey Frelick, said, "We are reiterating our rating on CPHD following CE-mark for its Xpert Chlamydia/gonorrhea (CT/NG) tests. We view commercialization of key tests as important pieces to the mosaic, as CPHD leverages its large installed base across a broad and expanding test menu that drives the important metric, “clinical reagent sales growth.”"
"CT/NG set to kick off in Europe. As expected, CPHD announced CE-mark for CT/NG, bringing its ex-US menu to 13 tests. We expect U.S. approval by yearend."
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $37.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- New Street Research Upgrades Micron Technology (MU) to Buy
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
